01 Industry overview
The endoscopy industry at a glance
The global endoscopy devices market is estimated at $66.1 billion in 2026, while demand is shifting toward single-use systems and higher-volume outpatient procedures.
- $66.1B[8]
- Global market, 2026
- 3.8%[8]
- Forecast CAGR, 2025–2030
- 39.8%[8]
- North America share, 2024
- 2.3M
- UK-Ireland procedures, 2025
- Market size
- The global endoscopy devices market was valued at $61.1 billion in 2024 and is estimated at $66.1 billion in 2026. The estimate covers endoscopes, visualization systems, visualization components and operative devices.[8]
- Forecast & CAGR
- The market is forecast to reach $76.6 billion by 2030, representing a 3.8% CAGR from 2025 to 2030. Ambu separately reports that the single-use endoscopy segment is growing at more than 20% annually, faster than the overall market.[8][23]
- Market share & regions
- North America held 39.8% of global endoscopy devices revenue in 2024, making it the largest regional market. A Mauna Kea annual report estimates approximately 14,700 endoscopy-room establishments in the United States, 15,000 in Europe and 30,000 in China and Japan.[8][24]
- Segmentation
- Endoscopes represented 41.1% of endoscopy devices revenue in 2024. The market is also segmented by visualization systems, visualization components and operative devices, and by end users such as hospitals and ambulatory care facilities.[8]
- Key players & concentration
- The industry includes large multinational suppliers such as Olympus, Boston Scientific, KARL STORZ, Stryker, Fujifilm, Medtronic, Ambu and CONMED. Ambu reported more than 60% global share of the single-use endoscopy segment in its 2025/26 annual report, indicating substantially higher concentration in that niche than in the broader endoscopy devices market.[23][25]
- Trends, drivers & challenges
- Growth is being supported by minimally invasive diagnosis and treatment, cancer-screening demand, rising procedure volumes and conversion from reusable to single-use devices. The main operational challenges are the cost of disposable systems, reprocessing complexity, infection-control requirements and shortages of trained endoscopy staff.[23][26][27]
- Consumer behavior & competition
- In the UK and Ireland, more than 2.3 million endoscopy procedures were uploaded to the national reporting system in 2025, up 8.2% from 2024; more than 2.4 million patients underwent an endoscopy procedure during the latest reported year. Competition is shifting toward image quality, therapeutic capability, workflow integration, artificial intelligence and single-use infection-control benefits.[23]
- M&A
- Ambu acquired U.S.-based TIMS Medical in September 2026 for an upfront payment of $45 million plus milestone payments of up to $20 million, adding hospital workflow and imaging integration with access to approximately 7,000 U.S. hospital installations. Getinge also announced the acquisition of UK distributor Pennamed in April 2026 to strengthen its endoscopy-unit offering.[28][29]
- Regulation
- In the United States, reusable endoscopes are regulated as semi-critical devices and require cleaning followed by high-level disinfection or sterilization between patients. FDA 510(k) submissions for specified endoscopes and automated endoscope reprocessors must include reprocessing validation data; the FDA has also supported transition toward disposable or disposable-component duodenoscopes to reduce infection risk.[26]
- Latest news
- The most recent identified industry transaction is Ambu’s September 14, 2026 acquisition of TIMS Medical, combining single-use endoscopy with imaging, reporting and hospital IT integration. Ambu said the deal supports its EndoIntelligence strategy and expands access to approximately 7,000 U.S. hospital installations.[28]
02 Ranking
Top 10 Companies in the Endoscopy Industry
The leading companies in the endoscopy industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 17, 2026 · Next review December 17, 2026
Boston Scientific stands out for gastrointestinal diagnosis and treatment devices because it develops and manufactures devices for GI endoscopy and endotherapy, while Stryker focuses on surgical endoscopy and visualization since it lists Endoscopy as a core business alongside surgical technologies and medical equipment.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in GI & surgical endoscopy devices
Boston Scientific
US
Ranked #1 · 9.5 · GI & surgical endoscopy devices
Why we picked it: It develops and manufactures devices for gastrointestinal diagnosis and treatment in GI endoscopy and endotherapy.
#2 overall
Stryker
US
Ranked #2 · 8.9 · GI & surgical endoscopy devices
Why we picked it: It lists endoscopy as a core business alongside surgical technologies and medical equipment.
Leader in flexible scope systems
HOYA
JP
Ranked #3 · 8.9 · Flexible scope systems
Why we picked it: It operates PENTAX Medical, supplying video scopes and fiberscopes for digestive, ENT, and respiratory care.
Pick 1 is the #1 company overall. Pick 2 is the highest-ranked company in the top 5 that adds a new segment; no further segment places in the top 5, so pick 3 follows rank.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Boston Scientific GI & surgical endoscopy devices · US | 9.5 | 9.9 | 9.6 | 9.9 | 9.1 | |
Company snapshot · Boston Scientific · Data as of November 17, 2026 Its Endoscopy business develops and manufactures devices for gastrointestinal diagnosis and treatment.[30]
| |||||||
| 2 | Stryker GI & surgical endoscopy devices · US | 8.9 | 9.7 | 8.7 | 8.8 | 8.1 | |
Company snapshot · Stryker · Data as of November 17, 2026 Stryker lists Endoscopy as a core business alongside surgical technologies and medical equipment.[31]
| |||||||
| 3 | HOYA Flexible scope systems · JP | 8.9 | 8.3 | 9.4 | 8.7 | 9.9 | |
Company snapshot · HOYA · Data as of November 17, 2026 HOYA operates PENTAX Medical, supplying video scopes and fiberscopes for digestive, ENT and respiratory care.[32]
| |||||||
| 4 | Olympus GI & surgical endoscopy devices · JP | 8.7 | 9.5 | 8.0 | 8.1 | 8.8 | |
Company snapshot · Olympus · Data as of November 17, 2026 Olympus reports endoscopy as its core medical business and the world's largest endoscope manufacturer.[25]
| |||||||
| 5 | Medtronic GI & surgical endoscopy devices · IE | 8.7 | 8.7 | 8.2 | 8.7 | 8.0 | |
Company snapshot · Medtronic · Data as of November 17, 2026 Medtronic reports a dedicated Surgical and Endoscopy division within its Medical Surgical portfolio.[33]
| |||||||
| 6 | Ovesco Endoscopy Advanced GI endoscopy devices · DE | 8.6 | 7.0 | 9.9 | 9.5 | 9.3 | |
Company snapshot · Ovesco Endoscopy · Data as of November 17, 2026 Ovesco develops advanced therapeutic devices for gastrointestinal endoscopy and endoluminal procedures.[34]
| |||||||
| 7 | Ambu Single-use respiratory, urology, ENT and GI endoscopy · DK | 8.5 | 8.7 | 7.7 | 8.6 | 9.3 | |
Company snapshot · Ambu · Data as of November 17, 2026 Ambu describes itself as the market leader in single-use endoscopy across four major endoscopy areas.[23]
| |||||||
| 8 | KARL STORZ Rigid, flexible and surgical endoscopy · DE | 8.4 | 9.2 | 7.1 | 7.8 | 9.3 | |
Company snapshot · KARL STORZ · Data as of November 17, 2026 KARL STORZ is a major manufacturer of rigid and flexible endoscopic systems for minimally invasive surgery.[35]
| |||||||
| 9 | Cook Medical GI endotherapy and endoscopic accessories · US | 8.3 | 8.0 | 8.6 | 8.1 | 8.7 | |
Company snapshot · Cook Medical · Data as of November 17, 2026 Cook Medical produces minimally invasive devices used in gastrointestinal endoscopy and therapeutic procedures.[36]
| |||||||
| 10 | Richard Wolf Rigid, flexible and minimally invasive endoscopy · DE | 8.1 | 7.0 | 8.5 | 8.9 | 8.0 | |
Company snapshot · Richard Wolf · Data as of November 17, 2026 Richard Wolf supplies precision endoscopic instruments through subsidiaries and distributors worldwide.[37]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 17, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Henrik Dahl. (2026, February 13). Top 10 companies in the endoscopy industry. In Endoscopy Industry Statistics. Gitnux. https://gitnux.org/endoscopy-industry-statistics/#top-companies
Revenue of the largest endoscopy companies
Stryker leads with $25.1B in annual revenue (group level, converted to USD).
03 Trends & forecasts
Top 10 Endoscopy Industry Trends & Forecasts 2027
What is changing in the endoscopy industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Single-use systems outpace reusable scopes
High confidenceAmbu reports that the single-use endoscopy market is growing at more than 20% annually, compared with an overall endoscopy devices market forecast CAGR of 3.8% for 2025–2030. Ambu also reports more than 60% global share of single-use endoscopy by market value in its 2025/26 annual report.[23]
Forecast 2027: In 2027, single-use systems should continue gaining share in bronchoscopy, urology, ENT and selected gastrointestinal procedures. Growth will remain substantially faster than the broader market, although disposable cost will limit replacement in high-volume routine procedures.
02Outpatient endoscopy expands further
Medium confidenceEndoscopy has grown by 46.7% among ambulatory surgery centers since 2017, according to ASC Data’s Q4 2025 insights report. The shift reflects demand for lower-cost, higher-throughput procedures outside inpatient hospitals.[38][39]
Forecast 2027: In 2027, ambulatory and office-based facilities should capture a larger share of routine colonoscopy, upper-GI and selected therapeutic procedures. Suppliers will increasingly tailor systems to compact rooms, rapid turnover and limited reprocessing infrastructure.
03AI-assisted detection moves toward routine use
High confidenceA 2025 meta-analysis of randomized trials found that AI-assisted colonoscopy increased adenoma detection by 20% and reduced adenoma miss rates by 55%. A 2026 randomized trial found right-colon adenoma detection of 36.4% with AI assistance versus 27.9% without it.[40][2]
Forecast 2027: By 2027, AI detection tools should become more common in new visualization platforms and large endoscopy networks. Adoption will be strongest where vendors can demonstrate workflow compatibility, manageable false-positive rates and measurable quality improvement.
04Workflow integration becomes a differentiator
High confidenceAmbu’s 2025/26 annual report identifies EMR integration and post-procedure documentation as part of its EndoIntelligence platform. Its September 2026 TIMS Medical acquisition adds imaging, reporting and hospital IT integration with access to approximately 7,000 U.S. hospital installations.[23]
Forecast 2027: In 2027, competition should increasingly center on connected procedure rooms rather than image quality alone. Vendors offering interoperable imaging, reporting, documentation and analytics should gain an advantage in enterprise purchasing decisions.
05Disposable components replace fixed designs
High confidenceThe FDA recommends that facilities transition from fixed-endcap duodenoscopes to devices with disposable components or fully disposable designs. The FDA reports contamination rates of 0.5% for one newer removable-component model versus rates as high as 6% for older designs.[26]
Forecast 2027: In 2027, disposable distal caps, elevators and other difficult-to-clean components should expand beyond duodenoscopes where clinically and economically practical. Fully disposable systems will remain concentrated in higher-risk or lower-volume applications.
06Reprocessing validation raises development costs
High confidenceFDA 510(k) submissions for reusable duodenoscopes and specified endoscopes must include validated reprocessing instructions and reprocessing validation data. The FDA lists duodenoscopes, gastroduodenoscopes and several other endoscope categories among devices requiring such validation data.[41][26]
Forecast 2027: In 2027, manufacturers will face greater design, testing and documentation costs for reusable products. This should favor simpler-to-clean architectures, disposable components and suppliers with established regulatory and human-factors capabilities.
07Infection control supports single-use conversion
High confidenceThe FDA continues to link duodenoscope safety to meticulous manual cleaning, high-level disinfection or sterilization, quality assurance and improved device design. It specifically recommends modern designs that facilitate or eliminate reprocessing.[26]
Forecast 2027: In 2027, infection-prevention requirements should remain a major purchasing argument for single-use scopes and disposable components. Hospitals will increasingly compare total infection-control workload, not only acquisition price.
08Automated reprocessing remains essential
High confidenceThe FDA describes automated endoscope reprocessors as widely used Class II devices that expose external surfaces and internal channels to high-level disinfectants or liquid chemical sterilants. The agency also stresses that automated cycles supplement, rather than replace, thorough manual cleaning.[26]
Forecast 2027: In 2027, demand for automated reprocessors, drying and storage systems, tracking software and validation services should rise alongside reusable scope volumes. Reprocessing suppliers will compete on compatibility, cycle time, traceability and staff-error reduction.
09Therapeutic capability gains importance
Medium confidenceThe 2025 JAG database recorded 40,737 ERCP procedures in 2024, up 17% from 2023, while EUS procedures reached 16,005. These advanced procedures require more capable visualization, accessories and integrated therapeutic platforms than routine diagnostic examinations.[15]
Forecast 2027: In 2027, vendors should prioritize platforms that support advanced imaging, EUS, ERCP, tissue acquisition, hemostasis and endoscopic resection. Revenue growth will increasingly come from higher-value therapeutic accessories and capital equipment rather than basic scopes alone.
10Endoscopy data becomes a quality asset
High confidenceThe UK National Endoscopy Database has recorded more than 15 million procedures since 2015, with around 200,000 procedures added monthly and more than 530 contributing sites in 2025. The database supports accreditation, training, research and quality improvement.[15]
Forecast 2027: In 2027, integrated procedure data should play a larger role in accreditation, benchmarking, staffing and vendor evaluations. Suppliers that make data export, audit and quality reporting easy should be better positioned in institutional tenders.
04 Statistics
Technology & AI
AI adoption shows measurable use and belief: 39% of 465 endoscopists reported AI experience in the 2024 WEO survey, with 90% expecting quality improvement.
AI and automation in the endoscopy industry
- 39% of 465 endoscopists from 83 countries reported experience using AI in clinical practice in the 2024 WEO survey.[1]
- 39.1% of 534 European gastroenterology respondents reported using LLMs for scientific writing, while 35.8% used them for administrative documentation, in 2025.[2]
- 90% of 465 international endoscopists believed AI would improve endoscopy quality, while 87% believed it would improve efficiency, in 2024.[1]
- 64.5% of 501 European gastroenterologists, gastroenterology residents and endoscopy practitioners believed LLMs could at least moderately support endoscopy-related practice in 2025.[2]
Tools, systems and equipment in the endoscopy industry
- In 2023–2024, endoscopy equipment shortages interfered with operation or service delivery at 17.3% of NHS services and 19.5% of independent services for OGD.[3]
- Reprocessing an endoscope required an estimated 59 minutes, including 23 minutes of hands-on nursing time, in the cited 2023 German endoscopy-unit estimate.[4]
- In 2023–2024, 23.3% of colonoscopy equipment in NHS services and 27.1% in independent services was more than 10 years old.[3]
- 12% of 465 endoscopy nurses in a 33-country survey assisted with single-use endoscopes monthly, 4% weekly and 3% daily during 2023.[4]
05 Statistics
Market Intelligence
Market scale moves in parallel with procedures: endoscopy devices are estimated at $66.1 billion in 2026, and endoscopy procedures are projected to reach $49.2 billion by 2030 from $34.3 billion in 2024.
Market size and service revenue in the endoscopy industry
- US$361 billion was the estimated 2024 global endoscopy-procedures market, covering diagnostic, therapeutic and other procedures by application, end user and region.[5]
- US$34.3 billion was the estimated 2024 global market for endoscopy procedures, covering diagnostic and therapeutic procedures across applications, end users and regions.[6]
Growth forecasts for the endoscopy industry
- The global endoscopy market is projected to grow from US$33.1 billion in 2026 to US$61.5 billion in 2035, a 7.1% CAGR; the scope includes endoscopy procedures and associated systems across hospitals and outpatient settings.[7]
- The global endoscopy-procedures market is projected to reach US$217.1 billion by 2033, with procedures growing at a 1.4% CAGR during 2026–2033.[8]
- The global endoscopy-procedures market is projected to reach US$49.2 billion by 2030 from US$34.3 billion in 2024, implying a 6.2% CAGR during 2024–2030.[6]
Regional breakdown of the endoscopy industry
- 15,474,990 colonoscopies were performed in the United States in 2022, according to claims-based estimates covering adults in the MarketScan Commercial Claims and Medicare Supplemental databases.[9]
- 295,528 upper-GI diagnostic endoscopy cases were reported statewide in Pennsylvania in 2024, including 139,758 ambulatory-surgery-center cases and 155,770 hospital-outpatient cases.[10]
- 43,283,828 digestive endoscopic procedures were performed in participating Chinese hospitals in 2023, including diagnostic and therapeutic EGD, colonoscopy, ESD, ERCP, EUS and capsule procedures.[2]
06 Statistics
Strategy & Growth
Integration and provider-side activity remain visible through deals: Boston Scientific paid $636 million for Apollo Endosurgery and integrated it into its Endoscopy division.
M&A and consolidation in the endoscopy industry
- $636 million was Boston Scientific’s upfront cash payment for Apollo Endosurgery, acquired on April 4, 2023 and integrated into Boston Scientific’s Endoscopy division.[11]
- U.S. gastroenterology physician-practice M&A declined from 27 deals in 2022 to 19 in 2023 and 11 in 2024, according to KPMG’s deal tracker covering publicly announced transactions.[12]
- 14 U.S. gastroenterology deals in 2023 comprised 2 growth investments, 11 add-ons to private-equity-backed platforms and 1 buyout, based on PESP’s tracked outpatient-care transactions.[13]
07 Statistics
Operating Benchmarks
Operational variance is measurable in quality and volume, including a 0.98% technical-failure rate for advanced endoscopy procedures at Orlando Health in June 2024.
Operating metrics used in the endoscopy industry
- 0.98% was the technical-failure rate for advanced endoscopy procedures at Orlando Health in June 2024, based on 921 procedures including ERCP, EUS, upper-GI, lower-GI, enteroscopy and third-space endoscopy.[14]
- 9,432.7 digestive endoscopies was the average annual volume per participating hospital in China in 2023; the dataset covered hospitals in the National Clinical Improvement System.[2]
- 1,189.4 endoscopy cases was the average annual workload per participating endoscopist in China in 2023, with tertiary-hospital endoscopists averaging 1,579.1 cases.[2]
08 Statistics
Delivery & Operations
System reporting is expanding: 535 UK endoscopy sites were uploading data to the National Endoscopy Database in 2024.
Delivery capacity and installed base in the endoscopy industry
- 7 dedicated recovery spaces per endoscopy service was the UK median in 2023, with an interquartile range of 3–14 across NHS and independent-sector services.[3]
- 535 UK endoscopy sites, including 315 NHS and 220 independent sites, were uploading data to the National Endoscopy Database in 2024.[15]
- 517 endoscopy services across the UK and Republic of Ireland were registered with JAG at December 2024, including 223 accredited services.[15]
- 1,062 endoscopy rooms were reported across 334 UK services in the 2023 national census: 860 NHS rooms and 202 independent-sector rooms.[3]
09 Statistics
Pricing
Cash facility prices show procedure-level dispersion across 2026 posted charges, including $1,614 for CPT 43235 and $2,125 for CPT 43239 across listed hospitals.
Fees and price levels in the endoscopy industry
- $1,614 was the median cash facility price for diagnostic upper endoscopy (CPT 43235) across 36 U.S. hospitals’ posted standard-charge files in 2026; category definition: hospital facility charge only.[16]
- $2,125 was the median cash facility price for upper endoscopy with biopsy (CPT 43239) across 38 U.S. hospitals’ posted standard-charge files in 2026; category definition: hospital facility charge only.[16]
- $1,109 was the average cash price for upper GI endoscopy at U.S. surgery centers versus $1,595 at outpatient hospitals in the 2026 pricing snapshot.[17]
10 Statistics
Finance
Ownership detail connects endoscopy devices and delivery economics, including Apollo-backed GI Alliance listings and AmSurg’s 51% ownership interest in Anesthesia Associates in 2024.
Ownership and investment in the endoscopy industry
- 150 centers were listed under Apollo-backed GI Alliance in Mercer Capital’s 2024 ambulatory-surgery-center ownership table, evidencing private-equity-backed ownership in the U.S. endoscopy provider segment.[18]
- 51% was AmSurg’s ownership interest in Anesthesia Associates, an anesthesia group wholly owned by Cascade Endoscopy Center, in Oregon in 2024.[19]
- 21 centers were listed under IRA Capital-backed Endoscopy Center of Southeast Texas in Mercer Capital’s 2024 ownership table.[18]
11 Statistics
Risk & Compliance
Compliance timelines are explicit in the US, including 60 calendar days for HIPAA breach notification and 6 years for required Security Rule documentation retention.
Client data and confidentiality in the endoscopy industry
- 60 calendar days is the maximum period for U.S. endoscopy providers to notify affected individuals and HHS after discovering a reportable breach; set by the HIPAA Breach Notification Rule, United States, in force under 45 CFR §§164.404 and 164.408.[20]
- 6 years is the minimum retention period for required Security Rule documentation maintained by U.S. endoscopy providers that are HIPAA covered entities; set by 45 CFR §164.316(b)(2)(i), United States, under the HIPAA Security Rule.[20]
- 500 individuals is the threshold at which U.S. endoscopy providers that are HIPAA covered entities must notify the HHS Secretary of a breach of unsecured protected health information; set by the HIPAA Breach Notification Rule, United States, in force under 45 CFR §§164.400–414.[20]
12 Statistics
Sustainability
Environmental impact metrics vary by setting and include reprocessing waste, with 303 kg of solid waste and 1,385 gallons of liquid reprocessing waste per 100 EGD or colonoscopy procedures in a US study.
Energy, emissions and disclosure in the endoscopy industry
- 38.45 kg CO2e per gastrointestinal endoscopy procedure was measured in Hyderabad, India, including patient travel, across 3,873 procedures conducted from May 29 to June 10, 2023.[21]
- 1,980 kWh of energy consumption and approximately 1,501 kg CO2e were associated with every 100 EGD or colonoscopy procedures in the same U.S. endoscopy-unit study.[22]
- 148,947.32 kg CO2e was the total footprint of 3,873 gastrointestinal endoscopy procedures in Hyderabad, India, during May 29–June 10, 2023.[21]
- 303 kg of solid waste and 1,385 gallons of liquid reprocessing waste were generated per 100 EGD or colonoscopy procedures in a U.S. tertiary academic endoscopy unit studied in May–June 2022.[22]
Key questions about the Endoscopy Industry
What is the 2026 size of the global endoscopy devices market?
How fast is the endoscopy devices market growing from 2025 to 2030?
Which companies lead the endoscopy industry?
What technology shift is accelerating in endoscopy through single-use systems?
How concentrated is single-use endoscopy compared with the broader devices market?
How do reprocessing validation requirements affect regulatory submissions in the US?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Henrik Dahl. (2026, February 13). Endoscopy Industry Statistics. Gitnux. https://gitnux.org/endoscopy-industry-statistics
Henrik Dahl. "Endoscopy Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/endoscopy-industry-statistics.
Henrik Dahl. 2026. "Endoscopy Industry Statistics." Gitnux. https://gitnux.org/endoscopy-industry-statistics.
Sources & references
41 sources cited across this report
esge.com
doi.org
fg.bmj.com
pmc.ncbi.nlm.nih.gov
alliedmarketresearch.com
giiresearch.com
gminsights.com
grandviewresearch.com
cghjournal.org
phc4.org
sec.gov
corporatefinance.kpmg.com
pestakeholder.org
orlandohealth.com
thejag.org.uk
treatcompare.com
cost.sidecarhealth.com
mercercapital.com
oregon.gov
hhs.gov
gut.bmj.com
gastrojournal.org
ambu.com
maunakeatech.com
olympus-global.com
fda.gov
asge.org
via.ritzau.dk
mb.cision.com
bostonscientific.com
stryker.com
hoya.com
news.medtronic.com
- ovesco.com
karlstorz.com
cookmedical.com
richard-wolf.com
ascnews.com
ascdata.com
giejournal.org
accessdata.fda.gov
